Stock Price, News, Quote and Profile of VANDA PHARMACEUTICALS INC(NASDAQ:VNDA) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

VANDA PHARMACEUTICALS INC

NASDAQ:VNDA (4/19/2024, 7:22:56 PM)

After market: 5.12 +0.01 (+0.2%)

5.11

+0.14 (+2.82%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap294.03M

PE102.2

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 290 full-time employees. The company went IPO on 2006-04-12. Its commercial portfolio comprises two products, HETLIOZ for the treatment of jet lag disorder, insomnia, delayed sleep phase disorder (DSPD), sleep disturbances in autism spectrum disorder (ASD) and pediatric Non-24 and Fanapt for the treatment of bipolar I disorder and Parkinsons disease psychosis and a long acting injectable (LAI) formulation for the treatment of schizophrenia. The company offers PONVORY, to treat adults with relapsing forms of multiple sclerosis (RMS) in the United States and Canada. The firm also has a range of drugs in development, including Tradipitant (VLY-686), for the treatment of gastroparesis, motion sickness, and atopic dermatitis; VTR-297 for the treatment of hematologic malignancies, and VQW-765, for the treatment of performance anxiety and psychiatric disorders.

Company Info

VANDA PHARMACEUTICALS INC

Suite 300E, 2200 Pennsylvania Ave Nw

WASHINGTON WASHINGTON DC 20037

P: 12027343400

CEO: Mihael H. Polymeropoulos

Employees: 290

Website: https://www.vandapharma.com/

VNDA News

3 days ago - ChartmillTop movers in Wednesday's session

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

3 days ago - ChartmillWhich stocks are experiencing notable movement on Wednesday?

Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.